CVS Group plc Exercise of SAYE Options and PDMR Dealing (5840Z)
January 12 2024 - 7:56AM
UK Regulatory
TIDMCVSG
RNS Number : 5840Z
CVS Group plc
12 January 2024
12 January 2024
CVS Group Plc
("CVS" or the "Company")
Exercise of SAYE Options and PDMR Dealing
CVS, one of the UK's leading providers of integrated veterinary
services, announces that on 10 January 2024, options over a total
of 41,174 ordinary shares of 0.2 pence each (the "Ordinary Shares")
were exercised under the CVS Group 2020 SAYE Plan (2020/2024), at
an exercise price of GBP10.09.
The issuance of shares in connection with the SAYE Exercise was
fully satisfied by 41,174 Ordinary Shares held by the CVS Group
Employee Benefit Trust (the "EBT"). Following the SAYE Exercise, a
total of 6,771 Ordinary Shares are held by the EBT, representing
approximately 0.009% of the Company's total voting rights.
Richard Fairman, Chief Executive Officer exercised options over
606 Ordinary Shares in the Company. The balance of the options were
exercised by certain other employees and former employees of the
Company.
Following his option exercise, Richard Fairman, along with any
persons closely associated, holds a beneficial interest in 78,107
Ordinary Shares in the Company, representing approximately 0.109%
of the total voting rights of the Company, calculated on the same
basis.
The notification below, made in accordance with the requirements
of the UK Market Abuse Regulation, provides further detail.
Contacts:
CVS Group plc via Camarco
Richard Fairman, CEO
Scott Morrison, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418
8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial PR)
Geoffrey Pelham-Lane +44 (0)7733 124 226
Ginny Pulbrook +44 (0)7961 315 138
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Richard Fairman
------------------------------- ----------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- ----------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name CVS Group plc
------------------------------- ----------------------------------
b) LEI 213800J41XDQ2NX48O05
------------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the financial Ordinary shares of 0.2 pence each
instrument, type of
instrument GB00B2863827
Identification code
b) Nature of the transaction Exercise of options under the 2020
SAYE Plan (1 January 2024 maturity)
----------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume
GBP10.09 606
----------------------------- ------------------------------------
d) Aggregated information
* Aggregated volume
N/A - single transaction
* Price
----------------------------- ------------------------------------
e) Date of the transaction 10 January 2024
----------------------------- ------------------------------------
f) Place of the transaction London Stock Exchange - AIM
----------------------------- ------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHXLLFFZFLEBBZ
(END) Dow Jones Newswires
January 12, 2024 08:56 ET (13:56 GMT)
CVS (AQSE:CVSG.GB)
Historical Stock Chart
From Oct 2024 to Nov 2024
CVS (AQSE:CVSG.GB)
Historical Stock Chart
From Nov 2023 to Nov 2024